Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Five Prime, Bristol-Myers Squibb cut $350M immuno-oncology deal.
Should You Believe Tesaro's Hype?
A new license for promising technology from AnaptysBio could eventually help increase the number of drugs in Tesaro's (TSRO) pipeline.
Are We in the Midst of Irrational Exuberance Version 2.0?
It's been 17 years since former Fed chief Alan Greenspan coined the term irrational exuberance, but frothy valuations are once again making the market look top-heavy.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.
Why Tesaro, magicJack VocalTec, and Scientific Games Are Today's 3 Best Stocks
Geopolitical tensions crush the S&P 500, but that didn't stop Tesaro, magicJack VocalTec, and Scientific Games from soaring.
Why Tesaro, Inc. Shares Skyrocketed
Tesaro shares soar after announcing a collaborative agreement. Will this deal change everything for Tesaro or is it not all that it's cracked up to be?
Partnership With AnaptysBio Gives Tesaro Entree to Immuno-Oncology
Partnership with AnaptysBio gives Tesaro entree to immuno-oncology.